相关实验视频

Updated: Jun 6, 2025

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

在晚期前列腺癌中消除获得的PARP抑制剂耐药性

George Seed¹, Nick Beije², Wei Yuan¹

¹The Institute of Cancer Research, London, UK.

|November 22, 2024

概括

PARP 抑制剂在前列腺癌中具有DNA 修复缺陷的抗瘤活性. 耐药性可以通过基因逆转出现,特别是在BRCA2被删除的瘤中,影响患者的生存.

科学领域:

在瘤学瘤学.
遗传学遗传学是一个
分子生物学分子生物学

背景情况:

PARP抑制 (PARPi) 在具有同源复合修复 (HRR) 缺陷的割耐性前列腺癌 (CRPC) 中显示出有效性.
需要进一步阐明PARPi耐药性的机制,特别是在BRCA2同胞性删除 (HomDel) CRPC中,需要进一步阐明.
恢复BRCA基因功能的获得突变是已知的抵抗机制,但它们的临床相关性和生成尚不清楚.

研究的目的:

研究CRPC中PARPi耐药性的机制,重点研究逆转突变及其临床影响.
为了分析BRCA2 HomDel CRPC患者中抗药的出现,患者接受PARPi治疗.
评估逆转事件与患者生存结果之间的关联.

主要方法:

对转移性CRPC的TOPARP-B试验患者样本的分析.
在BRCA2/PALB2突变瘤中识别和表征逆转突变.
使用单个循环瘤细胞基因组学,FISH和RNAish研究BRCA2 HomDel CRPC耐药性.

主要成果:

在治疗结束时,在79%的BRCA2/PALB2突变瘤中发现了逆转突变.
60%的移删除反转与微同学相伴,这表明了POLQ介导的修复.
逆转的频率和时间与无进展和整体存活率 (p < 0.01) 有显著的相关性.
在BRCA2 HomDel CRPC中,在PARPi治疗期间观察到缺乏BRCA2 HomDel的罕见亚克隆的选择.

结论:

通过逆转突变恢复HRR功能是CRPC中PARPi抗性的关键机制.
通过POLQ介导的修复在产生抗性突变方面发挥着作用.
了解这些抗性机制对于开发克服前列腺癌中PARPi抗性的策略至关重要.

关键词:

修复DNA的修复DNA的修复抑制PARP的抑制作用 cfDNA DNA 的时间.基因组学就是基因组学.前列腺癌是前列腺癌.逆转逆转逆转逆转

更多相关视频

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...